Transplant Genomics is harnessing the power of precision medicine to benefit kidney transplant recipients with tests that will help their doctors provide better care, keep their minds at ease, and possibly even extend their lives.

The Need for Non-Invasive Patient Managment

Biopsies have been used since 1951 and are still considered the gold standard for assessing kidney graft status. In many transplant programs patients are periodically subjected to these invasive procedures every so often as part of a surveillance program (so called “surveillance” or “protocol” biopsies) to help clinicians determine whether a patient is silently rejecting, with no test results indicating any problem, or if their immune system is truly adequately suppressed. This is done because studies have shown that as many as 25% of patients who appear to be just fine have actually begun to reject but existing non-invasive tests are too insensitive to detect it. However, 75% of all surveillance biopsies show no signs of kidney damage or rejection while subjecting stable patients to pain, inconvenience and risk of complications – possibly even graft loss. It’s time for a better solution.

TruGraf is the first non-invasive blood test clinicians can use to help assess whether their patients are adequately immunosuppressed, prior to a rise in their serum creatinine (at which point damage to the kidney has already occurred), without having to perform a risky invasive protocol biopsy.

How Can TruGraf Benefit You?

TruGraf results inform a clinician if a patient with stable renal function (normal serum creatinine results) is adequately immunosuppressed (classified as TX for Transplant eXcellence) or inadequately immunosuppressed (classified as Not-TX). Considered in the context of the other clinical information available, a TruGraf result may be critical in supporting a physician decision regarding setting appropriate medication levels or choosing other treatment options. Patients benefit by gaining peace of mind in the knowledge that their graft is doing well, or that their physician has been able to intervene earlier, and without having to perform a painful invasive biopsy, to make a more fully informed treatment decision.

TruGraf CAN:

  • Be used as an alternative or complement to protocol biopsies
  • Be run serially with any desired frequency, 24/7/365
  • Provide support for decisions to minimize immunosuppression
  • Reveal whether treatment for rejection has been successful without performing a biopsy
  • Can enable early intervention, possibly improve long term patient outcomes

Patients tell their stories...